60 results
8-K
EX-99.1
ORIC
ORIC Pharmaceuticals Inc
6 May 24
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
4:10pm
, pharmacodynamic, and safety results in patients with prostate cancer; proceeding into combination with AR inhibitor(s) in metastatic prostate cancer … engagement, and a well-tolerated safety profile.
Presented preclinical data at the 2024 AACR Annual Meeting demonstrating superior preclinical drug
S-3ASR
ORIC
ORIC Pharmaceuticals Inc
11 Mar 24
Automatic shelf registration
5:28pm
prediction of greater than 10 hours, robust target engagement and a favorable safety profile. We expect to initiate a combination study of ORIC-944 … properties, including clinical half-life consistent with a preclinical prediction of greater than 10 hours, robust target engagement and a favorable safety
8-K
EX-99.1
jpwuztu8at0pv55zdfaa
11 Mar 24
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
4:10pm
8-K
EX-99.1
cxui7q02xzk
9 Jan 24
Results of Operations and Financial Condition
9:00am
S-3
rfazv6mdbg gn
15 Dec 23
Shelf registration
4:32pm
8-K
EX-99.1
85zo3yac1q2rts
11 Dec 23
Other Events
4:05pm
8-K
EX-99.1
0r5 ruq05wg9km24
6 Nov 23
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
4:10pm
8-K
EX-99.1
yk93isl t4h
23 Oct 23
Other Events
4:07pm
8-K
EX-99.1
ue3kkam9qifxvcm
10 Aug 23
ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
4:11pm
8-K
EX-99.1
lula jb92ghi
27 Jun 23
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing
6:05am
8-K
EX-99.2
0muidaqnvxefx gaju8x
21 Dec 22
Other Events
5:25pm
424B5
smywtq64mma5a9xpwc
21 Dec 22
Prospectus supplement for primary offering
5:23pm